Q&A

Houston investor launches fund to fuel early-stage energy transition startups

Ahmad Atwan founded VC Fuel in Houston to fund the future of the energy transition. Photo courtesy of VC Fuel

When Ahmad Atwan decided he was going to launch a venture capital fund focused on early-stage energy transition startups, Houston was a no brainer. But while there are similar funds on each of the coasts, Atwan learned that VC Fuel's concept was going to be kind of niche for Houston.

"We're the only early stage climate tech or energy transition firm in Houston right now, which is really surprising," Atwan tells InnovationMap, explaining that the Bay Area is home to dozens of these funds and there are even more on the East Coast. "I'm hoping there'll be more (similar funds in Houston), but it's also kind of a nice position to be in."

Atwan shares more about VC Fuel and the $100 million fund, which he's still raising for while also investing in a few startups at the same time, in an interview with InnovationMap. He also discusses how his expertise as a former founder and former private equity investor with Morgan Stanley and BlackRock makes him an opportune value-add investor.

InnovationMap: Why did you decide to start VC fuel?

AhmadAtwan: I decided to start VC fuel because I've been in the energy industry my entire career. I've been both an entrepreneur — I started two companies in the 2000s that I sold. One was a energy technology firm and one was a Brazilian ethanol company.

After that I was on the buy side buying pretty large private energy companies — anywhere from the size of $500 million to $2 billion. And over that whole time, energy was a very exciting industry and was growing very fast.

But as I saw climate change happening more rapidly and becoming more of a reality, and as I started looking and investing in some renewable energy sources, like wind and solar, I realized that's really where my passion was and what I wanted to do. And at the same time, the world was moving towards that as well, and investors really wanted to have exposure to new energy or energy transition areas.

IM: What are you looking for in potential investment opportunities?

AA: The areas that we focus on are all decarbonized and kind of all across the board, ranging from clean agriculture, hydrogen, carbon capture and storage or carbon capture and usage, to energy efficiency, clean industrial processes, and more. And I think these are areas that they right now comprise less than 2 percent of the global energy mix, but they're going to be north of 10, 15, 20 percent over time. So, these are high growth areas, and they are either lower, zero, or even negative emissions.

We're looking specifically for companies that we call seed stage or series A, generally, sometimes series B. So, they're companies that are relatively early in their development, but have some sort of commercial traction. And ones that are looking for not only a venture capital firm, but someone that can be their partner and help guide them and help them in certain areas, like raising their next round of funding, helping them get introduced to customers.

IM: With your experience, what do you feel like you bring to the table as a hands-on investor?

AA: I think in my decade-plus in private equity, when I was an investor on the boards of a company, I always tended to be one of the most involved in helping guide operations and working with senior management. And I think that's probably because I was a founder in the past, so I really identify with founders and I try to figure out with them what's the gap in their skillset or knowledge base that needs to be filled. Sometimes it's one that I can naturally help fill, which might be on the financial side or on the commercial side. And sometimes it's just bringing in other experts to help the company out.

But I think having been both on the founder and the private equity side, I think I empathize with the founder usually. And I would give this advice to all founders out there: the most important relationship they're going to have is with their lead venture capitalist, because that's going to be the defining relationship that helps them get to legitimacy in terms of the next round of funding. It's something that I kind of learned from friends in Silicon Valley. It's not only building the relationship for VC fuel — it's building a relationship with one of the individuals in our firm, whether it's me or one of my partners, and having them be really invested in the company.

IM: Why did you decide on Houston for VC Fuel's HQ?

AA: First of all, Houston is the undisputed energy capital of the world. So to me, especially when you're looking at energy transition sectors that have to work with the energy industry, it was a no brainer. For a lot of the technologies we deal with — like carbon capture — and the businesses we deal with, it's going to be essential for them to connect with the energy world.

I think a second reason, frankly, and I didn't realize this until we really got deep into the idea is that we're a little bit unique and we have a little bit of a competitive advantage. There are over 30 climate tech firms in the Bay Area, and there are a large number as well in New York and Boston. We're the only early stage climate tech or energy transition firm in Houston right now, which is really surprising. And I'm hoping there'll be more of those, but that's also kind of a nice position to be in because, as we see opportunities come out of the energy companies, and as we try to attract talent and grow, we think we have a pretty unique offering.

IM: What has being located in Greentown Houston meant for you?

AA: It's been fantastic. I think Houston did a great job of attracting Greentown here as the second location. Working out of here, we're able to interact in real time with everything from startup companies to major corporations. You get such a diverse set of people who are passionate about energy transition. It's actually already led to some opportunities to invest in, as well as to connect with some of the bigger companies that want to invest with us. It's been just a great coincidence that we launched here when Greentown opened. We'd much rather be here than any other type of working space. So, we're very excited.

IM: What keeps you up at night as it pertains to the energy transition?

AA: I would say the first thing is commercial adoption. All of our companies so far have great management teams — especially founders — and excellent technology, but there's that bridge to actually get the technology adopted by a customer. Sometimes you can have the best technology, and it just never happens. So, I'm keeping my eye on how much progress are we making with commercial customers. A lot of these are big companies — whether it's a waste management or a tech company, like a Microsoft — are getting into energy transition. Customer adoption in that area is a key metric for us.

The second big one — and this one's a little newer to me because I didn't face it as much in the past — is regulation. So many of the areas that we look at are going to have their economics determined by regulations that are literally being written right now. For example, the Cares Act the by the Biden administration is deciding things like what the level of tax credits will be for carbon capture. The carbon capture company we've invested in suddenly sees their projects become a lot more profitable if that figure is on the higher side. It's important to keep our ear to the ground on regulation and try to anticipate where it's going. That's why we have a couple people who are ex-Department of Energy on our advisory board because we like to have that skill set.

IM: What's next for VC Fuel?

AA: Our cadence of investing is that we invest in about one company every couple of months, which is pretty fast for a venture capital firm in energy transition. What's next is for our current companies to get to the next stage of evolution. There is one that I can't talk about specifically, but it might be getting sold to a really exciting buyer — and it's very good to have that kind of exit early on in a fund's life. And for the rest of our portfolio companies it's about continuing to get customers and next rounds of funding.

We've done a really good job of building a portfolio. That's not concentrated in any one area of energy transition. We will continue to look for a diverse set of companies that compliment each other, and that can help each other out. One area we continue to look at is not just the carbon capture, but also the carbon use space where you can turn carbon into something that's actually productive. Another area that we continue to look at is the electric vehicle space, but not just traditional EVs, but the next generation EV technology.

------

This conversation has been edited for brevity and clarity.

Trending News

 
 

Promoted

Emerson Perin of the Texas Heart Institute, recently published the largest clinical trial of cell therapy for patients with chronic heart failure to-date included 580 patients at 52 sites throughout North America. Photo via texasheart.org

Emerson Perin’s end goal isn’t to treat heart failure. The medical director of The Texas Heart Institute says that he has his sights set firmly on curing the malady altogether. And, with the power of innovation and a strong team, the Houston-based cardiologist has a good chance of meeting his objective.

Perin first came to THI for fellowship training in 1988, following his residency in Miami and medical school in his birthplace of Brazil.

“This is a very special place,” the physician and researcher, whose titles also include director for THI’s Center for Clinical Research and vice president for medical affairs, tells InnovationMap. “It has a worldwide-reaching reputation. I’ve always liked research and this is a great place in terms of innovation and practicing high-level cardiology.”

For decades, Perin has followed in THI founder Denton Cooley’s footsteps with world-changing research. In 2001, the founding medical director of THI’s Stem Cell Center was the first person to inject stem cells into a failing human heart. It led to a trial of 17 patients that year.

“A couple of the patients did remarkably well — more than you could ever expect. These guys who couldn’t’ walk across the room pretty much were jogging on the beach. That gave me the initial insight that this works,” Perin recalls.

What exactly is heart failure? The term refers to the condition of a heart that can’t pump enough blood to sustainably power the body through oxygenation of the tissues from blood flow. It may sound like a death sentence, but with appropriate care, it can usually be managed with medicines and if worsening occurs, devices and, ultimately, heart transplantation.

And Perin is proving that there’s a lot of life ahead for heart failure patients. Earlier this year, he published another groundbreaking clinical trial, DREAM-HF. The largest clinical trial of cell therapy for patients with chronic heart failure to-date included 580 patients at 52 sites throughout North America.

With the goal of getting a new cell therapy approved for heart failure, the primary endpoint was to prove that the therapy could prevent recurrent hospitalizations.

“It was a total negative,” says Perin. That’s because the cells don’t have a decongestant effect such as the medicines currently used to treat heart failure.

But that doesn’t mean that the trial was a failure. Quite the opposite. That’s because Perin and his team proved something else: The trial was able to prove that there was significant improvement in patients with inflammation. After those patients were injected with mesenchymal precursor cells (MPC), they showed a 70-percent reduction in heart attacks and strokes. Cardiovascular deaths also decreased.

These are blockbuster numbers, and big news for patients dealing with heart failure. What it means is that the cells addressed a different aspect of heart failure that until now had been left untreated which was the inflammation — how heart failure starts and what keeps it going.

So what’s next? Going to the FDA.

“They said, ‘We can’t approve it with one trial, but we’ll approve it with two,’” says Perin.

This time, his primary endpoint will be tailored to suit the positive outcome he knows he’ll be able achieve. This next round will begin in 2024.

Once the FDA approves a new catheter system for injecting the heart with stem cells and genes, the team will proceed with new studies. Gene therapy will be another frontier for Perin — and patients with heart failure.

“I think the combination of cells and genes is even more powerful,” he says. “That will help save lives in a completely new way and do away with heart failure.”

Perin's work is just one piece of the puzzle, and Dr. Joseph Rogers, who was appointed president and CEO of THI in 2021, is leading the organization's initiative in several ways. THI, recently buoyed by a $32 million donation from a patient — the largest charitable donation in its history — is exploring several innovative therapeutics, devices, and treatments.

THI recently received a two-year, $1.14 million grant from The National Heart, Lung, and Blood Institute to develop a novel, first-in-class drug to treat the cardiovascular disease that arises from atherosclerosis. Another THI innovator, Camila Hochman-Mendez — along with her research team — is studying the effects of regenerative medicine on hearts.

Trending News

 
 

Promoted